2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-122672
    Adhesamine 462605-73-8 98.04%
    Adhesamine, dumbbell-shaped molecule, activates MAPK/FAK pathway. Adhesamine promotes adhesion and growth of mammalian cells. Adhesamine accelerates the differentiation and improves the survival of mice hippocampal neurons in primary culture.
    Adhesamine
  • HY-123178
    Fenpropathrin 39515-41-8 99.86%
    Fenpropathrin is a synthetic pyrethroid insecticide in agriculture. Fenpropathrin may induces parkinsonian symptoms progressively.
    Fenpropathrin
  • HY-124151
    Adenosine-2'-monophosphate 130-49-4 ≥98.0%
    Adenosine-2'-monophosphate (2'-AMP) is converted by extracellular 2’,3'-CAMP. Adenosine-2'-monophosphate is further metabolized to extracellular adenosine (a mechanism called the extracellular 2’,3’-cAMP-adenosine pathway). Adenosine-2'-monophosphate inhibits LPS-induced TNF-α and CXCL10 production via A2A receptor activation.
    Adenosine-2'-monophosphate
  • HY-12710A
    Rauwolscine hydrochloride 6211-32-1 ≥98.0%
    Rauwolscine hydrochloride is a potent and specific α2 adrenergic receptor antagonist with a Ki of 12 nM.
    Rauwolscine hydrochloride
  • HY-12749A
    Midodrine hydrochloride 43218-56-0 ≥99.0%
    Midodrine hydrochloride ((±)-Midodrine hydrochloride) is an α1-receptor agonist, for the treatment of dysautonomia and orthostatic hypotension.
    Midodrine hydrochloride
  • HY-128057
    NCRW0005-F05 342779-66-2 ≥99.0%
    NCRW0005-F05 is a potent GPR139 antagonist with an IC50 value of 0.21 μM. NCRW0005-F05 can be used to research diabetes, obesity and Parkinson's disease.
    NCRW0005-F05
  • HY-128971
    LHVS 170111-28-1
    LHVS is a potent, non-selective, irreversible, cell-permeable cysteine protease and cathepsin inhibitor. LHVS decreases actin ring formation. LHVS inhibits T. gondii invasion with an IC50 of 10 μM.
    LHVS
  • HY-131592
    Tricetin 520-31-0
    Tricetin is a potent competitive inhibitor of the Keap1-Nrf2 Protein Protein Interaction (PPI). Tricetin protects against 6-OHDA-induced neurotoxicity in Parkinson's disease model by activating Nrf2/HO-1 signaling pathway and preventing mitochondria-dependent apoptosis pathway.
    Tricetin
  • HY-134992
    Vazegepant 1337918-83-8 99.54%
    Vazegepant (Zavegepant) is an orally active calcitonin gene-related peptide CGRP receptor antagonist with potential for acute research in migraine, can be administered intranasally. CGRP is an important trigger in migraine pathophysiology.
    Vazegepant
  • HY-136780
    SEN177 2117405-13-5 98.76%
    SEN177 is an orally effect glutamine cyclase (QC) inhibitor. The Ki of SEN177 for human glutamine cyclase (hQC) is 20 nM, and the IC50 is 13 nM. SEN177 interferes with the interaction between CD47 and SIRRPα, and has anti-tumor activity. SEN177 reduces aggregation and apoptosis caused by HTT mutation in Huntington model, and can be used in the study of neurodegenerative diseases.
    SEN177
  • HY-139048
    Fluoroethylnormemantine 1639210-26-6 ≥98.0%
    Fluoroethylnormemantine, a derivative of Memantine, is an antagonist of the N-methyl-D-aspartate (NMDA) receptor. [18F]-Fluoroethylnormemantine can be used as a positron emission tomography (PET) tracer. Fluoroethylnormemantine exhibits anti-amnesic, neuroprotective, antidepressant-like and fear-attenuating effects.
    Fluoroethylnormemantine
  • HY-14406A
    L-733060 hydrochloride 148687-76-7 ≥99.0%
    L-733060 hydrochloride is a potent tachykinin NK1 receptor antagonist. L-733060 hydrochloride inhibits neurogenic plasma extravasation at doses that do not cause adverse cardiovascular effects in rodents and also acts as an antitumoral agent.
    L-733060 hydrochloride
  • HY-148349
    PF-07258669 2755890-53-8 98.44%
    PF-07258669 is an orally active melanocortin-4 receptor (MC4R) antagonist that antagonizes MC4R with an IC50 of 13 nM (Ki=0.46 nM). PF-07258669 can be used for the research of cachexia, anorexia, or anorexia nervosa.
    PF-07258669
  • HY-155021
    PROTAC α-synuclein degrader 5 2781922-42-5 99.95%
    PROTAC α-synuclein degrader 5 is a highly selective small-molecule degraders (PROTAC) of α-synuclein aggregates, with an DC50 of 7.51 μM and the highest degradation rate Dmax of 89%. PROTAC α-synuclein degrader 5 contains probe molecule sery308 and E3 ligase ligands. PROTAC α-synuclein degrader 5 can be used for neurological disease research.
    PROTAC α-synuclein degrader 5
  • HY-156650
    Votoplam 2407849-89-0 99.51%
    Votoplam is an HTT gene regulator with an IC50 ≤ 0.1 μM. Votoplam can be used in the research of Huntington's disease.
    Votoplam
  • HY-16677A
    Mofegiline hydrochloride 120635-25-8
    Mofegiline hydrochloride (MDL72974A) is an orally active and selective enzyme-activated irreversible inhibitor of MAO-B, with marked selectivity on the MAO-B over MAO-A with IC50s of 3.6 nM (MAO-B) and 680 nM (MAO-A), respectively. Mofegiline hydrochloride is also an inhibitor of semicarbazide-sensitive amine oxidase (SSAO).
    Mofegiline hydrochloride
  • HY-A0019A
    Paliperidone palmitate 199739-10-1 98.41%
    Paliperidone palmitate is an orally effective competitive antagonist of dopamine D2 receptors and 5-hydroxytryptamine 2A (5-HT2A) receptors that can cross the blood-brain barrier. Paliperidone palmitate competitively inhibits the effects of dopamine and 5-hydroxytryptamine by binding to dopamine D2 receptors and 5-HT2A receptors, regulating the balance of the neurotransmitter system and thus exerting antipsychotic activity. Paliperidone palmitate is mainly used in the research field of schizophrenia.
    Paliperidone palmitate
  • HY-B0274A
    Chlorprothixene hydrochloride 6469-93-8 ≥98.0%
    Chlorprothixene hydrochloride is a dopamine and histamine receptors antagonist with Kis of 18 nM, 2.96 nM, 4.56 nM, 9 nM and 3.75 nM for hD1, hD2, hD3, hD5 and hH1 receptors, respectively. Antipsychotic activity.
    Chlorprothixene hydrochloride
  • HY-B0661A
    Tamsulosin hydrochloride 106463-17-6 99.81%
    Tamsulosin hydrochloride ((R)-(-)-YM12617 free base) is an orally active antagonist of α1-adrenergic receptor. Tamsulosin hydrochloride induces Apoptosis. Tamsulosin hydrochloride is used for the research of prostatic hyperplasia. Tamsulosin hydrochloride attenuates abdominal aortic aneurysm growth and inhibits inflammation in animal models.
    Tamsulosin hydrochloride
  • HY-B0807A
    Prochlorperazine dimaleate 84-02-6 ≥98.0%
    Prochlorperazine dimaleate is a first-generation antipsychotic. Prochlorperazine dimaleate can be used in the research of chemotherapy-induced nausea and vomiting (CINV). Prochlorperazine dimaleate also possesses anticancer activity. Prochlorperazine dimaleate exhibits IC50 values of 6.4 μM, 4.5 μM and 2.3 μM for NOX1, NOX2 and NOX5, respectively.
    Prochlorperazine dimaleate
Cat. No. Product Name / Synonyms Application Reactivity